Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
Clinical trial NCT03672136 · UNKNOWN
Trial details
- NCT number
- NCT03672136
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-01
- Primary completion
- 2019-11-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.